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The search for new drugs against Streptococcus pneu-
moniae (pneumococcus) is driven by the 1.5 million
deaths it causes annually. Choline-binding proteins at-
tach to the pneumococcal cell wall through domains
that recognize choline moieties, and their involvement
in pneumococcal virulence makes them potential tar-
gets for drug development. We have defined chemical
criteria involved in the docking of small molecules from
a three-dimensional structural library to the major
pneumococcal autolysin (LytA) choline binding domain.
These criteria were used to identify compounds that
could interfere with the attachment of this protein to
the cell wall, and several quinolones that fit this frame-
work were found to inhibit the cell wall-degrading ac-
tivity of LytA. Furthermore, these compounds produced
similar effects on other enzymes with different catalytic
activities but that contained a similar choline binding
domain; that is, autolysin (LytC) and the phage lytic
enzyme (Cpl-1). Finally, we resolved the crystal struc-
ture of the complex between the choline binding domain
of LytA and ofloxacin at a resolution of 2.6 Å. These data
constitute an important launch pad from which effec-
tive drugs to combat pneumococcal infections can
be developed.
Streptococcus pneumoniae (pneumococcus) causes high mor-
bidity and mortality worldwide through infections such as
pneumonia, bacteremia, meningitis, acute otitis media, and
sinusitis (1). The current scenario in which the vaccines avail-
able are not fully efficient and the resistance to antibiotics is
ever-increasing makes the discovery of new drugs against this
human pathogen rather urgent (2, 3). Among the determinants
of pneumococcus virulence that have been identified (4), much
attention is currently being focused on a family of surface-
exposed polypeptides known as choline-binding proteins
(ChBPs).1 The interest in these polypeptides has arisen be-
cause they are implicated in pathogenic processes such as
adhesion to host cells, nasopharyngeal colonization, and bacte-
rial sepsis (5). Although these enzymes contain different cata-
lytic domains that account for a wide range of functions, they
do all share a choline binding domain (ChBD) that consists of a
series of 20-amino acid-long imperfect choline binding re-
peats (6).2 The ChBD is responsible for the non-covalent
anchoring of the ChBPs to the choline moieties of both teichoic
and lipoteichoic acids at the cell surface (8). This peculiar
attachment to the cell surface is essential for their contribution
to bacterial virulence.
Three ChBPs catalyze the degradation of the pneumococcal
murein when cell wall biosynthesis ceases, each one cleaving
the peptidoglycan backbone at a different site (for review, see
Ref. 9). Of these, the major autolysin (LytA) is an amidase (9),
whereas the two minor peptidoglycan hydrolases (LytB and
LytC) function as a glucosaminidase (10) and a lysozyme (11),
respectively. LytA and LytC are responsible of the autolytic
release of toxins like pneumolysin, which by irritating the host
tissues allows pneumococcus to gain access to the bloodstream.
It is in this way that the bacteria invade the lungs and the
brain, causing bacteremia, meningitis, and pneumonia (5, 12).
In many cases the ChBPs modulate their own enzyme activ-
ity. Thus, in the case of LytA, the full-length protein obtained
from ethanolamine-grown pneumococci or expressed in Esche-
richia coli remains in the inactive E-form until it is preincu-
bated with 150 mM choline (13, 14). However, although the
enzyme requires a high concentration of choline for its conver-
sion to the active C-form, its activity remains largely undetect-
able unless the choline concentrations are lowered. This appar-
ent paradox arises through the competition between the free
amino alcohol and the choline moieties of the teichoic/lipotei-
choic acids in the pneumococcal cell wall. The enzymatic activ-
ity of LytA depends on its binding to the cell wall, which is
inhibited when it interacts with the free choline (15). Further-
more, in vivo experiments have shown that the sequestering of
LytA by the lipoteichoic acids of the plasma membrane has a
similar inhibitory effect (16). In addition, certain ChBPs such
as LytA are irreversibly denatured in the absence of choline.
We recently described the crystal structure of the ChBD in
LytA complexed with choline (17, 18). This dimeric structure
reveals a novel solenoid fold consisting exclusively of  hairpins
that stack to form a left-handed superhelix. This superhelix is
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stabilized by choline molecules at the hydrophobic interface of
consecutive hairpins. Four choline-binding sites (ChBSs) are
found per monomer, and all the forces contributing to the
interaction between the protein and choline molecules are hy-
drophobic, with an electrostatic cation- contribution. We have
used this crystal structure to screen a data base of small
organic molecules to find new lead compounds that may dimin-
ish pneumococcal virulence by preventing the binding of Ch-
BPs to the cell wall. One such lead compound singled out in the
screening procedure was ofloxacin, which mimics an inhibitor
of its anchoring to the pneumococcal cell wall and of its enzy-
matic activity. With a view to providing a more precise basis for
pursuing these leads, the crystal structure of the ChBD from
LytA complexed to ofloxacin was resolved.
EXPERIMENTAL PROCEDURES
Purification of Lytic Enzymes—The biochemical characteristics of
the pneumococcal autolysins LytA and LytC as well as those of the
phage-coded lysines Cpl-1 and Cpl-7 have been recently reviewed (19).
All these enzymes were overexpressed in E. coli and purified to elec-
trophoretic homogeneity either by affinity chromatography on diethyl-
aminoethanol (DEAE)-cellulose (LytA, LytC, and Cpl-1) (20, 21) or by
using (NH4)2SO4 fractionation and gel filtration (22).
In Vitro Evaluation of the Inhibition of LytA Binding to the Cell
Wall—An in vitro test based on the similarity between choline and
DEAE was devised to evaluate the capacity of compounds to interfere
with the binding of LytA to the cell wall. This similarity was used to
devise an affinity chromatography-based purification protocol for this
protein (23, 24). A sonicated extract from E. coli overexpressing either
full-length LytA or its ChBD (17) was prepared in 50 mM Tris-HCl, pH
6.5, 0.1 M NaCl buffer. This extract was centrifuged, and the superna-
tant was mixed with 2 ml of DEAE-Sephacel (Amersham Biosciences)
pre-equilibrated in the same buffer. The pellet recovered was then
washed extensively with 50 mM Tris-HCl, pH 6.5, 1.5 M NaCl and
divided in aliquots that were loaded into small chromatography col-
umns. These columns were prepared using 0.5 ml of bench-top centri-
fuge ultrafiltration cartridges of 0.45-m cutoff (Millipore), and they
were eluted with 1 ml of the sonication buffer containing the compound
to be tested (0.5 to 25 mM, depending on the solubility of the compound;
Sigma-Aldrich). A solution containing 25 mM choline chloride was used
as the positive control and the sonication buffer as a negative control.
All steps were performed at 4 °C. The presence of LytA (or its ChBD) in
the eluted fractions was assessed by SDS-polyacrylamide gel electro-
phoresis (acrylamide 15%; acrylamide/bisacrylamide ratio, 30:1).
Conversion Tests and Cell Wall Degradation Assays—For this assay
we have adapted the protocol of Garcı´a et al. (14). In brief, inactive LytA
(E-form) overexpressed in E. coli was converted by incubating it at 4 °C
with either 10 or 25 mM ofloxacin (Sigma). It was then subjected to the
cell wall degradation assay as described previously (16). To evaluate the
inhibition of cell wall degradation activity, the pure converted LytA
amidase was tested in the presence of increasing concentrations of the
different compounds under study (usually between 0.01 and 50 mM). As
a control these reactions were performed with an equivalent concentra-
tion of choline chloride (Sigma), and all measurements were taken in
quadruplicate. The same procedure was employed with LytC, Cpl-1,
and Cpl-7 except that the 0.2 M sodium phosphate buffer used was
adjusted to pH 6.0 rather than to 6.9.
Structure-based Library Screening—The program AutoDock 3.0 (25)
was chosen to analyze the computational docking of the compounds of
the National Cancer Institute “Diversity” set data base with the ChBSs
of LytA. For each ligand, hydrogen atoms and charges (Gasteiger) were
added with SYBYL (SYBYL, Version 6.7, Tripos Inc., MO, www.
tripos.com). The same program was used to add polar hydrogen atoms
and Kollman united-atom partial atomic charges to the macromolecular
structures. For the geometric representation of the macromolecular
structure, the grids were approximately centered on the coordinates of
the choline N atoms present in the crystal structure. The size of the
grids (22.5  22.5  22.5 Å3) was sufficient to include the entire ChBSs
and provide enough space for random translation and rotational walk-
ing of the ligand across the surface. The grid spacing was taken to be
0.375 Å. The original Lennard-Jones and the hydrogen bonding poten-
tials obtained using the Lamarckian genetic algorithm for docking were
identical for all docking operations and are summarized in Table I.
Protein Preparation for Crystallization—To obtain crystals of the
complex between the ChBD of LytA and ofloxacin, choline had to be
removed from the protein sample. Therefore, the buffer used generally
to elute the protein from the DEAE-Sephacel resin (50 mM Tris-HCl, pH
6.5, 0.1 M NaCl, 150 mM choline chloride) was switched to one in which
choline was substituted with 5 mM ofloxacin (Sigma). The ChBD of LytA
eluted under these conditions was stable in the absence of choline,
which suggests that ofloxacin somehow mimics choline in stabilizing
the general architecture of LytA. Protein/ofloxacin crystals were grown
from a 12 mg/ml solution of the protein using the sitting drop vapor
diffusion method at 295 K over a well solution of 2 M ammonium sulfate
and 2% (w/v) polyethylene glycol 400 buffered with 0.1 M HEPES, pH
7.5. The typical crystal size was about 0.1  0.1  0.4 mm.
Data Collection and Structure Determination—Diffraction data of
single crystals were collected at 100 K with a MAR CCD detector with
synchrotron radiation at the BM14S beamline from the European Syn-
chrotron Radiation Facility (Grenoble, France). A single dataset was
collected on a crystal diffracting to 2.6 Å. Data were processed with
MOSFLM (26) and the CCP4 suite of programs (27). The crystals
belonged to the P21212 space group (a  101.7 Å, b  94.5 Å, c  38.1 Å)
with one dimer per asymmetric unit. The structure was determined by
molecular replacement with AMoRe (28) using the coordinates of the
ChBD of LytA complexed with choline (Protein Data Bank entry 1hcx)
as a search model. Several cycles of simulated annealing and B-factor
refinement were carried out using CNS (29) until the Rwork and Rfree
values dropped to 22.0 and 28.0%, respectively. Bulk solvent and aniso-
tropic overall B factor corrections were applied throughout the refine-
ment. Molecules at the ChBSs were only added to the densities evident
in both the 2 Fo  Fc and the Fo  Fc electron density maps after four
refinement cycles. In the final model, which was validated using PRO-
CHECK (30), no backbone ,  torsions angles were located in the
disallowed region of the Ramachandran plot, whereas 83% of the resi-
dues were located in the most favored regions.
RESULTS
Docking of small Mr Compounds into the ChBSs—We set out
to identify lead compounds that might assist in the design of
novel drugs to treat pneumococcus infections. To this end
TABLE I
Autodock parameters used for flexible docking
Genetic algorithm (ga) and Lamarckian genetic algorithm parameters
ga_pop_size Number of individuals in population 50
ga_num_evals Maximum number of energy evaluations 250,000
ga_num_generations Maximum number of generations 27,000
ga_elitism Number of top individuals that automatically survive 1
ga_mutation_rate Rate of gene mutation 0.02
ga_crossover_rate Rate of crossover 0.80
ga_window_size Number of generations for picking worst individual 10
ga_cauchy_alpha Mean of cauchy distribution for gene mutation 0
ga_cauchy_beta Variance of cauchy distribution for gene mutation 1
Local search parameters
sw_max_its Number of iterations of Solis and Wets local search 300
sw_max_succ Number of consecutive successes before changing rho 4
sw_max_fail Number of consecutive failures before changing rho 4
sw_rho Size of local search space to sample 1.0
sw_lb_rho Lower bound on rho 0.01
ls_search_freq Probability of performing local search on an individual 0.06
Inhibition of Pneumococcal Virulence Factors 19949
 at CSIC - Centro de Investigaciones Biológicas on D
ecem
ber 28, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
TABLE II
Docking results with AutoDock 3.0
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molecular modeling studies were carried out using the crystal
structure of the LytA ChBD to find small molecules that
could block the interaction of this domain with the cell wall of
pneumococcus. The program AutoDock 3.0 (25) has been suc-
cessfully used to predict HIV-1 protease inhibitor binding
(31) and the binding of haptens to antibodies (32). Thus, we
used this software to analyze the docking process. The coor-
dinates for the protein templates were those deposited in the
Protein Data Bank after eliminating all the choline and wa-
ter molecules (ID code 1hcx). To reduce the total calculation
time, we employed a pre-filtered collection of small molecules
known as the Diversity set data base. This data base was
derived from the almost 140,000 compounds available at the
National Cancer Institute Developmental Therapeutics Pro-
gram by selection of defined pharmacophores (33). The re-
sulting list includes some 1,990 compounds that was further
reduced by excluding those 167 ligands containing halogen or
phosphor atoms because we found it difficult to deal with
their energy calculation parameters.
AutoDock is designed to analyze the docking of small flexible
ligands to a rigid protein. For this reason, different conforma-
tions of the four ChBSs of the monomeric ChBD cannot be
explored using this program despite their high degree topolog-
ical similarity. Consequently, four different docking operations
for the 1823 compounds had to be performed. Choline was
docked as a positive control, and in most cases, the final
docked conformation was very similar to the one present in
the crystal structure (not shown). The 20 best-score solutions
yielded final docking energy values 2.5 times higher than
choline (Table II).
TABLE II— continued
1 129.43.27.140/ncidb2.
2 The average values for choline and dextrofloxacin are 3.8  0.4 and 6.0  0.6, respectively.
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The final docked conformations of the 20 best-score ligands
were visualized using Turbo-Frodo (34). Although the three-
dimensional structures of these compounds are different, they
seem to share certain characteristic structural features (Fig. 1).
All the compounds contained a set of rings (almost invariably
6–8) that belong to the class of the planar or non-planar poly-
cyclic structures. The small hydrophobic cavity that constitutes
the ChBSs was always occupied by one or more of these rings.
The planar rings generally bound in groups of 2–4, indicating
that the docking of individual planar rings into the ChBSs does
not seem to be energetically favored. In contrast, the non-
planar structures bound through 1, 3, 4, or 5 rings, in which N
or O atoms sometimes appear. They generally established hy-
drogen bonds with specific protein residues in the surroundings
of the ChBSs.
Compounds Interacting with ChBSs under Physiological
Conditions—Although the National Cancer Institute Diversity
data base contains almost 2000 freely available compounds,
these cannot be acquired in large enough quantities to carry
out activity assays. Moreover, most of the best-score solutions
obtained from the docking analysis are not soluble in aqueous
solution, hampering the analysis of their activity under phys-
iological conditions. As an alternative, we tested a set of com-
mercially available compounds with a simple structure that
retained most of the important structural features of the best
docking compounds summarized above (Table III).
An initial estimate of the ability of compounds to interact
with ChBSs and subsequently release LytA from the cell wall
was carried out using DEAE-Sephacel (see “Experimental Pro-
cedures” and Table III). Only one of these compounds, ofloxa-
cin, released LytA from the DEAE-Sephacel in a similar man-
ner to choline (Fig. 2, lanes S and P). This compound is a chiral
molecule, commercially available as a racemic mixture of levo-
and dextrofloxacin. Elution was achieved at a concentration of
4 mM, and it had a similar effect when either full-length LytA
or its ChBD alone was bound to the resin (not shown). Further-
more, at a concentration of 25 mM ofloxacin, like free choline,
was also able to convert LytA from the inactive E-form to the
active C-form (not shown).
High Resolution Structure of C-LytA Bound to Ofloxacin—
We analyzed crystals of the complex between the LytA ChBD
and ofloxacin, and the data processing and refinement statis-
tics of a single crystal diffracting to 2.6 Å are presented in
Table IV. The corresponding structure represents a dimer of
the LytA ChBD, which has the same characteristics as the
previously reported crystal structures of the protein (17, 18).
Polyethylene glycol molecules occupy most ChBSs, whereas
only the ChBS2 of one monomer contains ofloxacin. As men-
tioned, ofloxacin is a chiral molecule, and the enantiomer that
best fitted the electron density maps was dextrofloxacin. Both
the 2Fo  Fc and Fo  Fc Fourier maps clearly showed the
presence of the dextrofloxacin molecule (Fig. 3A). The isolated
non-planar methylpiperazine ring is completely inserted into
the ChBS, probably mimicking the function of the hydrophobic
head of choline (Fig. 3B). In contrast, the double-aromatic,
planar system holding the negatively charged carboxylic group
points toward the solvent. The methyl constituent of the piper-
azine ring points directly toward the Met residue in ChBS. The
fluorine atom establishes a hydrogen bond with a water mole-
cule, which is also hydrogen-bonded to the N atom of Trp-220
(Fig. 4A). It is important to note that the planar system par-
tially interacts with the aromatic ring of a Tyr residue from a
symmetric protein molecule. Docking of ofloxacin using the
AutoDock program shows that this compound fit the ChBSs
with a geometry reminiscent to that observed in the crystal
structure (Fig. 4B). Although in the docked model, the dextro-
floxacin molecule is positioned in a conformation slightly dif-
ferent from that observed in the crystal structure, the pipera-
zine moiety fit into the ChBS, establishing similar hydrophobic
interactions with the side chains of Trp-220 and Trp-228. Dif-
ferences may be attributed to limitations of the energies pa-
rameters used by the AutoDock program.
Inhibition of Cell Wall Degradation by Ofloxacin and Related
Compounds—The interaction of ofloxacin with the ChBSs
shown in the high resolution structure would be expected to
release LytA from the cell wall and, consequently, to inhibit its
pneumococcal cell wall-degrading activity. This is indeed the
case, and its inhibitory activity appeared to be similar to that of
choline (Table V). Furthermore, as might have been expected
from the sequence homology among ChBDs (35), this fluoro-
quinolone specifically inhibited other enzymes whose activity
requires their attachment to the cell wall through ChBDs.
Indeed, the minor pneumococcal lysozyme LytC and the Cpl-1
lysozyme encoded by the pneumococcal phage Cp-1 are both
inhibited by ofloxacin at concentrations below those required
for choline (Table V). However, the choline-independent Cpl-7
lysozyme (35), which has a catalytic N-terminal domain virtu-
ally identical to that of Cpl-1 but lacks the ChBD, was not
affected by ofloxacin even at the high concentrations (50 mM).
The piperazine ring of ofloxacin that interacts with the LytA
ChBD is also present in norfloxacin, lomefloxacin, and pipe-
midic acid. Accordingly, the capacity of these three compounds
to inhibit the cell wall-degrading activity of LytA was also
tested. These compounds, with the exception of pipemidic acid,
proved to be better inhibitors of the cell wall degrading activity
of LytA. In our experiments, they showed an activity at least
FIG. 1. Selected examples of the best-score docking solutions. The protein structure is represented in yellow at the back of the figure, with
the aromatic residues of the ChBS as ball and stick. Compounds 373529_2 (A), 116490 (B), and 128609 (C) are docked onto the ChBS of the protein
and are shown at the front as ball and stick, with the C, O, and N atoms colored black, red, and blue, respectively. In our crystal structure (green
rods), choline has been included in the figure to illustrate the results of the docking.
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one order of magnitude greater than both choline and ofloxacin
(Table V).
Despite the structural similarities between ofloxacin and
norfloxacin, lomefloxacin, or pipemidic acid (Table III), none of
these three compounds was capable of releasing LytA protein
from DEAE-Sephacel. This was unexpected since they inhibit
its cell wall degrading activity and, thus, should all hinder the
attachment of LytA to the cell wall (Table V). Similarly, at-
tempts to crystallize these compounds bound to the ChBD of
LytA also failed because the protein aggregated during the
dialysis aimed to exchange choline from the affinity chroma-
tography elution buffer. This could be attributed either to the
TABLE III
Compounds tested in vitro for ChBs binding
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poor solubility of these compounds at the adequate pH values
required for protein stability. Alternatively, they may be inca-
pable of mimicking the stabilizing effect of choline on the Ch-
BDs. Both these reasons may also explain why norfloxacin,
lomefloxacin, and pipemidic acid fail to elute LytA from DEAE-
Sephacel. Nevertheless, their activity as specific inhibitors
seems to suggest that they are able to effectively release LytA
from its attachment to choline residues of the cell wall although
they fail to stabilize the ChBD architecture in solution.
DISCUSSION
Although the virulence of pneumococcus is a major health
concern, it is commonly accepted that the absence of ChBPs in
the cell wall makes this bacteria remarkably less virulent
(5, 36). For this reason, these proteins have attracted much
attention as potential targets for drug development. Because
cell wall attachment is essential for the enzymatic activity of
ChBPs, forcing the release of these proteins from the cell wall
with compounds that occupy the ChBSs might be an effective
therapeutic approach (17). In addition, some of these enzymes
can be activated by choline binding, and it might be possible to
competitively impair this conversion (13, 14). Indeed, certain
compounds might even promote the accumulation of the en-
zyme in the inactive state by displacing choline. Finally, be-
cause choline seems to be important in stabilizing the three-
dimensional structure of certain ChBPs (17, 18), it seems
worthwhile exploring whether compounds that displace choline
from the ChBSs may lack its stabilizing properties. These three
therapeutic strategies are all obviously based on irreversibly
displacing choline from its binding sites.
In the pursuit of chemicals that might give rise to the devel-
opment of new drugs, efforts have been concentrated on two
fronts, experimental high-throughput screening of compounds
and virtual library searches using computational methods, a
procedure known as structure-based drug design (37, 38). This
latter procedure is faster and cheaper, but it requires that an
atomic model of the target protein is available. The availability
of the ChBD crystal structure from LytA at a resolution of 2.6 Å
(17) prompted us to search a library to identify compounds
that might fit into the ChBS structure defined in this atomic
model.
We initially performed a docking search of a three-dimen-
sional structure data base containing almost 2000 compounds,
which yielded a list of 20 putative ChBSs ligands. The interac-
tion energies of these 20 ligands were at least twice that cal-
culated for choline (Table II). These results must be considered
as an approximation given the intrinsic problems of the cur-
rently available docking programs. For example, in general,
flexible docking is only applied to the ligand and not to the
macromolecule. Moreover, the scoring functions employed in-
volve several simplifications and as such do not account for
solvent molecules and some entropic contributions that may be
essential for the correct estimation of protein-ligand affinity.
The compounds that were of most interest based on the
docking calculations (Table II) are freely available from the
National Cancer Institute but cannot be acquired in suffi-
ciently large quantities for activity assays. Furthermore, most
of them are not soluble in aqueous solution, which hampers
their study in biologically relevant conditions. For these rea-
sons the docking results could only be employed to establish a
few rules to single out commercially available compounds
whose interaction with ChBDs could be tested under physio-
logical conditions.
Ofloxacin, a piperazine-containing fluoroquinolone, emerged
as an active compound against the cell wall anchorage of pneu-
mococcal LytA. We found that ofloxacin attaches to the ChBD
of LytA through its piperazine moiety. Furthermore, it mimics
choline in the enzyme conversion process, in the stabilization of
the ChBD architecture, and in the inhibition of the protein cell
wall degrading activity. We found that this inhibition is specif-
ically mediated by the interaction of ofloxacin with the ChBD of
LytA. Moreover, we demonstrate that other piperazine-con-
taining quinolones, such as norfloxacin, lomefloxacin, and pipe-
midic acid, also inhibit the enzymatic activity of LytA.
The irreversible denaturalization of LytA in the dialysis
experiments, aimed to exchange choline with either norfloxa-
cin, lomefloxacin, or pipemidic acid, has no straightforward
interpretation but could be a phenomenon of certain interest. It
is well known that LytA is not stable in the absence of choline,
a feature easily explained by the three-dimensional structure
of its ChBD bound to choline (17). Therefore, the instability
observed in the dialysis experiments could be explained purely
on the basis of choline dilution. This does not occur when
ofloxacin is included in the dialysis buffers since the three-
dimensional structure presented here shows that ofloxacin can
assume the structural role of choline in stabilizing the ChBD of
LytA. It is surprising that this stabilization does not occur with
norfloxacin and lomefloxacin, given that they are considerably
more efficient inhibitors of LytA activity than choline or
FIG. 2. Elution of LytA ChBD from DEAE-Sephacel minicol-
umns by ofloxacin. SDS-PAGE analysis of the protein eluted with 4
mM ofloxacin (lane S), 25 mM choline (lane P), and the vehicle (lane N).
Lane C corresponds to an E. coli crude extract of cells overexpressing
the ChBD of LytA (arrow). Equivalent results were obtained with
full-length LytA.
TABLE IV
Data collection, phasing, and refinement statistics
Data collection statistics
Space group P21212
Cell dimensions (Å) a  101.7, b  94.5, c  38.1
No. molecules/asymmetric unit 2
Wavelength (Å) 1.0163
Resolution (Å) 40.0–2.6
Measurements 107,594
Unique reflections 9,925
Rsym (%)
a 6.3 (27.2)
I/(I)a 8.6 (2.6)
Completeness (%)a 87.1 (91.5)
Structure determination
statistics
Molecular replacement C-factor 33.4
Molecular replacement R-factor 48.8
Refinement statistics
Resolution range (Å) 6.0–2.6
Reflections (work/free)b 8,402/743
Rwork/Rfree (%) 22.0/28.0
Root mean square deviations
Bond lengths (Å) 0.008
Bond angles (°) 1.3
Dihedral angles (°) 24.6
Number of atoms
Protein 2,108
Polyethylene glycol/ofloxacin 108
Solvent 56
Average B factor (Å2) 46.6
a Values in parentheses correspond to the highest resolution shell
(2.74–2.60 Å).
b Reflections in the test set represent 8% of the total number of
reflections.
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ofloxacin. However, it appears to be clear that neither the
interaction of norfloxacin nor lomefloxacin with the ChBD of
LytA stabilizes the three-dimensional structure in the same
way as choline and ofloxacin. Further studies with ChBPs that
do not irreversibly denature in the absence of choline (39) may
help to resolve this dilemma.
Fluoroquinolone antimicrobial agents were introduced in the
1980s and show considerable bactericidal activity against a
broad spectrum of Gram-positive and Gram-negative microor-
ganisms, including S. pneumoniae (40, 41). Their targets are,
preferentially, DNA gyrase in the case of Gram-negative and
topoisomerase IV among the Gram-positive bacteria (42, 43).
The development of these antibacterial agents was the result of
intense research aimed at improving the stability, decreasing
the affinity and broadening the activity spectrum of the lead
compounds 7-chloroquinoline and nalidixic acid. A piperazine
group that occupies the choline site in the three-dimensional
structure shown here was introduced to extend the half-life of
these antimicrobial agents at a certain stage of development.
However, the experiments described here suggest that pipera-
zine, when attached to a bulky group, may constitute a new
avenue to develop inhibitors of pneumococcal virulence, target-
ing factors such as the autolytic enzyme LytA. Moreover, the
data suggest that this sort of compound may have the same
effect on other pneumococcal cell wall-degrading enzymes like
LytC, which has been shown to be critical for the nasopharyn-
geal colonization stage of infection by this bacterium (5). The
inhibition of totally different ChBPs (LytA, LytC, and Cpl-1) by
the compounds that displace choline, like the ofloxacin-like
compounds reported here, confirms that the ChBDs from dif-
ferent proteins have a similar architecture. Furthermore, this
range of activity also suggests that this sort of compound may
be used to inhibit the whole family of pneumococcal (and other
Gram-positive bacteria) virulent microorganisms, which have
virulence factors belonging to the ChBP family (44). Finally,
because choline-containing teichoic acids are essential for
pneumococcal viability in vivo, the appearance of mutant
strains resistant to these new ChBS-targeted antimicrobial
agents should be a rare event.
The future pharmacological relevance of the lead compounds
outlined in the above will depend on how much their affinity for
ChBDs can be boosted. The diversity in the inhibition of LytA
by different piperazine-containing quinolones suggests that
chemical alteration of this ring to modify affinity is indeed a
possibility. Indeed, the crystal structure and the inhibition
data presented here may provide a basis for future develop-
ments in such a direction. Moreover, the results shown here
combined with studies aimed to establish the molecular basis of
the role of the ChBDs in the conversion of certain ChBPs from
the inactive to the active form and of the putative denaturation
FIG. 3. Crystal structure of dextrofloxacin bound to a ChBS of C-LytA. A, stereo view of the 2 Fo  Fc map of dextrofloxacin in the ChBS
of C-LytA, contoured at 1 . Density is well defined for the dextrofloxacin molecule. All the molecules have been represented as ball and stick.
Yellow, red, blue, and green have been used to color C, O, N, and F atoms, respectively. B, a solid surface representation of the ChBS with bound
dextrofloxacin. The hydrophobic residues and the dextrofloxacin molecule are represented as ball and stick, with C, O, N, and F atoms colored
yellow, red, blue, and magenta, respectively. The electrostatic surface potential contoured from 15 (intense red) to 15 kiloteslas (intense blue).
The figure was generated with GRASP (45).
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of LytA by norfloxacin, lomefloxacin, and pipemidic acid might
also open additional pathways for the development of novel
drugs against very important bacterial diseases.
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